BioLineRx Change In Working Capital from 2010 to 2024

BLRX Stock  USD 0.27  0.01  3.57%   
BioLineRx Change In Working Capital yearly trend continues to be fairly stable with very little volatility. Change In Working Capital is likely to outpace its year average in 2024. Change In Working Capital is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. View All Fundamentals
 
Change In Working Capital  
First Reported
2010-03-31
Previous Quarter
-10.8 M
Current Value
-7.2 M
Quarterly Volatility
2.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 2.3 M or Selling General Administrative of 17.5 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 8.27. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.
  
Check out the analysis of BioLineRx Correlation against competitors.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Latest BioLineRx's Change In Working Capital Growth Pattern

Below is the plot of the Change In Working Capital of BioLineRx over the last few years. It is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. BioLineRx's Change In Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioLineRx's overall financial position and show how it may be relating to other accounts over time.
Change In Working Capital10 Years Trend
Slightly volatile
   Change In Working Capital   
       Timeline  

BioLineRx Change In Working Capital Regression Statistics

Arithmetic Mean2,584,287
Geometric Mean1,281,492
Coefficient Of Variation219.81
Mean Deviation3,943,095
Median411,000
Standard Deviation5,680,423
Sample Variance32.3T
Range19.6M
R-Value0.52
Mean Square Error25.4T
R-Squared0.27
Significance0.05
Slope657,273
Total Sum of Squares451.7T

BioLineRx Change In Working Capital History

202416 M
202315.2 M
20221.2 M
2021-540 K
2020-1.3 M
20194.3 M
2018-1.7 M

About BioLineRx Financial Statements

BioLineRx investors use historical fundamental indicators, such as BioLineRx's Change In Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change In Working Capital15.2 M16 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.